Compare OVBC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | VERU |
|---|---|---|
| Founded | 1872 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.7M | 36.8M |
| IPO Year | 1996 | 1996 |
| Metric | OVBC | VERU |
|---|---|---|
| Price | $42.26 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 8.9K | ★ 49.2K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.75 | $0.36 |
| 52 Week High | $44.80 | $4.59 |
| Indicator | OVBC | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 41.21 |
| Support Level | $34.53 | $2.15 |
| Resistance Level | $44.73 | $2.70 |
| Average True Range (ATR) | 1.25 | 0.11 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 71.23 | 23.53 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services within Southeastern Ohio as well as western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers and other standard banking products and services.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.